BEIJING, Aug. 21, 2026 /PRNewswire/ — Personalized mRNA cancer therapy has recently reached an important milestone. An international Phase 3 study in high-risk melanoma reported positive results, further supporting the clinical potential of personalized neoantigen therapy and drawing renewed attention to clinical development and translational progress in China.
Among the companies advancing in this field, Beijing-based Likang Life Sciences is among the more clinically advanced developers in China’s personalized mRNA cancer vaccine sector.
Clinical Development of Personalized mRNA Cancer Vaccines Accelerates in China
In 2023, LK101, developed by Likang Life Sciences, received clinical trial clearance from China’s Center for Drug Evaluation. Beijing government sources described it as the first personalized mRNA cancer vaccine in China to receive clearance to enter clinical trials. In February 2025, LK101 also received U.S. FDA IND clearance, with clinical development continuing to advance.
Unlike conventional oncology drugs, personalized neoantigen therapies require tumor sequencing, mutation analysis, target selection and product design to be carried out separately for each patient. Their development and manufacturing are therefore more complex and depend heavily on the integration of sequencing, algorithms, clinical resources and individualized manufacturing capabilities.
LK101 targets patient-specific tumor neoantigens and uses an autologous dendritic-cell platform loaded with personalized neoantigen mRNA, an approach known as mRNA-DC. High-throughput sequencing and AI-assisted neoantigen analysis are used to identify and design individualized tumor antigens for each patient.
From its initial clinical clearance in China in 2023 to continued clinical development in 2025, domestic personalized mRNA cancer vaccine programs represented by LK101 are moving from early exploration toward deeper clinical validation.
From Clinical Trials to Translational Application in Hainan
Alongside conventional drug development, China is also exploring a distinctive translational pathway for some personalized cancer therapies.
In April 2025, a technology developed by Likang Life Sciences was used for its first translational application under the biomedical new technology framework in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan.
The technology follows the same personalized neoantigen mRNA-DC approach as LK101, which is under clinical development. Under Lecheng’s biomedical new technology translational application framework, its standardized regulatory name now translates as “Technology for Activating Personalized Antigen-Specific Immune Cells to Treat Malignant Tumors.”
Under relevant Hainan policies, qualifying biomedical new technologies may undergo clinical research and translational application in the Lecheng pilot zone, with fees permitted following the required filing and price disclosure procedures. This allows certain frontier technologies that are still under clinical development to enter real-world clinical settings within a defined regulatory framework.
This is not equivalent to formal drug marketing approval, but it provides a pathway for personalized therapies to move from clinical research toward practical medical application.
In June 2026, construction also began on Likang Life Sciences’ new drug R&D and manufacturing center in the Beijing Economic-Technological Development Area. The approximately RMB 110 million project will include what they describe as China’s first “AI + personalized target” tumor vaccine production line, with completion expected in October 2026.
For personalized therapies, the significance of such a production line goes beyond simply expanding capacity.
A “one patient, one medicine” model does not fit neatly into the conventional pharmaceutical model of lowering unit costs through large-batch standardized production. The ability to integrate sequencing, AI-assisted target selection, individualized design, cell preparation, quality control and clinical delivery into a more efficient manufacturing system may ultimately determine whether personalized cancer therapy can move from a frontier treatment for a limited number of patients toward broader use.
Could China’s Innovative Drug Sector Have Its Own “DeepSeek Moment”?
Over the past year, the term “DeepSeek moment” has often been used to describe how Chinese companies can develop a different competitive model in high-technology industries through engineering efficiency and innovation in cost structures.
Applied to personalized cancer therapy, however, the more important question may not be whether China can replicate an established global leader.
Rather, as personalized neoantigen therapies receive increasingly advanced clinical validation, the question is whether Chinese developers can use algorithms, manufacturing capabilities, supply chains and translational efficiency to produce and deliver highly individualized treatments more efficiently and ultimately make them available to more patients.
China’s personalized cancer therapy sector is still some distance from a true “DeepSeek moment.” But recent positive results from an international Phase 3 study suggest that the field has entered a new stage of development.
In the past, the industry first had to answer:
Can personalized mRNA cancer therapy deliver meaningful clinical value?
The next question may be:
Who can make it faster, more consistent and more efficient — and bring it to more patients?
And that race is only beginning.